To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM

Summary

A multicenter, randomized, double blind, placebo controlled, parallel, phase Ⅲ study to evaluate the efficacy and safety of JW0201 added on in patients with type 2 diabetes mellitus who have inadequate glycemic control with C2202 and C2204

Timeline

Start

2023-01-12

Primary completion

2024-03-21

Completion

2024-03-21

Drugs

Indications